Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Euvax B®: Hepatitis B vaccine
Euvax B: Hepatitis B vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Hexaxim® Group | EXPERIMENTAL | Subjects that received Hexaxim® in Study A3L12 |
| Infanrix® hexa Group | EXPERIMENTAL | Subjects that received Infanrix® hexa in Study A3L12 |
| Name | Type | Description |
|---|---|---|
| Euvax B®: Hepatitis B vaccine | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: * Informed consent form signed by subject's parent/legally acceptable representative * Assent form signed by subject * Subject and parent(s)/legally acceptable representatives able to attend the scheduled visits and to comply with all trial procedures * Receipt of primary vaccin...
Top 6 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Viread, Tenofovir alafenamide |
| Vir Biotechnology, Inc. | VIR | 6 | PHASE3 | Tobevibart, Elebsiran |
| Bausch Health Companies Inc. | BHC | 1 | PHASE3 | Larsucosterol |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Daplusiran/Tomligisiran, Bepirovirsen |
| Aligos Therapeutics, Inc. | ALGS | 1 | PHASE2 | ALG-000184 |
| Precision BioSciences, Inc. | DTIL | 2 | PHASE1 | PBGENE-HBV |
Euvax B is a hepatitis B vaccine used to prevent hepatitis B infection. It is a vaccine in the infectious disease therapeutic area, developed by Sanofi. The vaccine is given to stimulate immune protection against the hepatitis B virus, and it has been studied in a Phase 3 clinical trial in Thailand.
Euvax B is made by Sanofi, which trades under the ticker SNY. Sanofi develops and manufactures the hepatitis B vaccine. The product is also written as Euvax B® with the registered trademark symbol.
Euvax B has been evaluated in a Phase 3 clinical trial, and that trial is completed. The program has one completed Phase 3 study with no active trials listed. The available record does not indicate that Euvax B is approved by the FDA, so it should be regarded as a vaccine candidate in clinical development.
Euvax B was studied in the Phase 3 trial NCT02697474, titled Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine. The trial enrolled 150 participants in Thailand, included healthy volunteers of all sexes from age 9 years, and is completed.
Yes, Euvax B and Euvax B® refer to the same hepatitis B vaccine from Sanofi. The ® symbol simply marks the registered trademark version of the name. Both names identify the same vaccine product studied in the Phase 3 trial NCT02697474 for hepatitis B.
Euvax B is used for prevention of hepatitis B, an infectious disease of the liver. It is a vaccine modality developed by Sanofi. Its Phase 3 trial NCT02697474 assessed anti-hepatitis B antibodies at age 9 to 10 years after hepatitis B vaccination at birth and a DTaP-IPV-Hep B-PRP-T hexavalent vaccine.